Baillie Gifford & Co’s CRISPR Therapeutics CRSP Stock Holding History

Baillie Gifford & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-364,768	Closed	-$17.1M	–	275
2024 Q3	$17.1M	Sell	364,768 -40,657	-10%	-$2.06M	0.01%	189
2024 Q2	$21.9M	Buy	405,425 +9,510	+2%	+$550K	0.02%	176
2024 Q1	$27M	Sell	395,915 -26,848	-6%	-$1.92M	0.02%	175
2023 Q4	$26.5M	Sell	422,763 -18,300	-4%	-$1.01M	0.02%	177
2023 Q3	$20M	Buy	441,063 +197,469	+81%	+$10.2M	0.02%	185
2023 Q2	$13.7M	Sell	243,594 -19,757	-8%	-$1.12M	0.01%	204
2023 Q1	$11.9M	Hold	263,351	–	–	0.01%	210
2022 Q4	$10.7M	Sell	263,351 -25,202	-9%	-$1.34M	0.01%	217
2022 Q3	$18.9M	Buy	+288,553	New	+$20.9M	0.02%	189

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co's CRSP Position: Q4 2024 in Review

Baillie Gifford & Co sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 364,768 shares — an estimated $17.1M sold.

Baillie Gifford & Co first reported a position in CRSP in Q3 2022 and held it in 9 quarters. The position peaked at $27M in Q1 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Baillie Gifford & Co reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Baillie Gifford & Co sold 364,768 CRISPR Therapeutics shares in Q4 2024, an estimated $17.1M.
Baillie Gifford & Co first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 9 quarters.
Baillie Gifford & Co's CRISPR Therapeutics position peaked at $27M in Q1 2024.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.